Elimination of the toxic effect of copper sulfate is accompanied by the normalization of liver function in fibrosis


V. N. Karazin Kharkov National University, Kharkov, Ukraine

Introduction

As is well-known, the liver plays a leading role in the formation of the body’s adaptive responses to the action of various environmental factors. Transformation, detoxification, and elimination of xenobiotics from the body are carried out due to the functional activity of the liver (Williams & Iatropoulos, 2002; Parkinson & Ogilvie, 2008; Piven et al., 2020; Slivinska et al., 2021). Excessive load on the functional activity of the liver is accompanied by the formation of liver pathologies, which manifests itself as hepatitis, fibrosis, cirrhosis of the liver (Puche et al., 2011; Jaramillo-Juárez et al., 2008), which may be accompanied by the formation of comorbid states (Poordad, 2015).

Pathogenetic factors of the liver are classified into biogenic (viruses, microorganisms), physical (radiation, electromagnetic fields), chemical (heavy metal ions and a wide range of hepatotoxic poisons); drugs, and even some types of food and alcoholic beverages (Lynes et al., 2007; Gao & Bataller, 2011; Satapathy et al., 2015; Hinova et al., 2016).

In this regard, the liver can be considered as a metabolic mediator between environmental factors and the body, in the sense that it transforms “the actions of environmental factors into metabolic reactions of the body”, while actively rebuilding its metabolism, which is quite often accompanied by the formation of chronic pathologies – fibrosis and cirrhosis of the liver. In 2017, 1.32 million people died from irreversible liver pathology (Buchanan & Sinclair, 2020), chronic liver pathologies and cirrhosis were diagnosed in 1.8% (4.5 million people) of the US population and are included in the list of 10 most common causes of death in developed countries (Sepanlou et al., 2017). The development of “protection” and treatment of liver diseases is an urgent biomedical and social problem since the number of people suffering from various liver pathologies in the world is even more than documented.

Currently, the main approaches to solving this problem are reduced to: 1 – elimination of negative hepatotoxic factors (Francavilla et al., 1994; Myers et al., 2002); 2 – development of means for regulating liver function, in particular, hepatoprotectors; 3 – development of regenerative medicine – and, first of all, cell therapy (Mason & Manzotti, 2010; Bozhkov et al., 2014); 4 – improving the methods of liver transplantation (Rana & Godfrey, 2019).

Currently, a huge number of hepatoprotective drugs have been developed (Verma et al., 2013; Saito et al., 2016; Shirani et al., 2017; Xu et al., 2018; Owojuyigbe et al., 2020). However, their effectiveness, especially to fibrosis, cirrhosis, and oncological processes in the liver, is rather low, and in most cases, they have side effects on the body (Shirani et al., 2017; Fahrney et al., 2020).

In this regard, it is necessary to search for new natural means of regulating liver functions. As in this case, along with various functions, the liver is capable of regeneration (Francavilla et al., 1994; Michalopoulos & DeFrances, 1997; Gagliano et al., 2007). The induction of regenerative processes in the liver involves a variety of signaling molecules, including such nonspecific components as “products” of cell hydrolysis. It has been suggested that low molecular weight components from various biological...
sources, which are formed as a result of molecular hydrolysis, may have a hepatoprotective effect (Bozhkov et al., 2017).

We believe that the main problem in the regulation of liver function, in particular in fibrosis, can be solved by the development of new substances of biological origin.

To test this hypothesis, we obtained a biologically active substance, which includes low molecular weight proteins and peptides (with a molecular weight of no more than 30 kDa) – 21.0%, oligosaccharides – 67.0%, lipids – 11.0%, vitamins, and minerals – 1.0%. Then there is a wide range of biologically active components of the Pleurotus ostreatus and Saccharomyces cerevisiae fungi (Kurguzova et al., 2015), and its hepatoprotective action was assessed experimentally and clinically.

Previous studies have shown that biologically active components from P. ostreatus and S. cerevisiae can eliminate acute infectious diarrhea (colibacillosis) in experimental animals (calves, piglets), modulate the immune system, reduce the manifestation of oxidative stress, and normalize liver function in the case of induced liver fibrosis in animals, increase the performance of animals in tests swimming with a load, against the background of toxic poisoning with copper ions (Bozhkov et al., 2016).

Since metal ions, and in particular copper ions, are inducers of the development of liver fibrosis (Lakherval, 2014), in this work we determined the ability of biologically active components from P. ostreatus and S. cerevisiae to prevent the death of experimental animals (Wistar rats), in acute poisoning with copper sulfate, some indicators of the redox system of the cell (activity of aconitase, glutathione peroxidase and the content of lipid hydroperoxides in liver mitochondria), which change with liver fibrosis. In liver pathologies some of the hepatocytes are destroyed, which is accompanied by the transition of several ALT and AST transferases from hepatocytes into the bloodstream (which is most often used in the diagnosis of liver pathology). Therefore, the activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST), as well as bilirubin, as an index of the product of hemoglobin hydrolysis in patients with hepatitis and liver fibrosis was also estimated.

Materials and methods

Experiments on laboratory animals, including assessing the effect of copper sulfate, were carried out in agreement with the ethical committee of V. N. Karazin, which is guided by the provisions of the “European Convention for the Protection of Vertebrate Animals used for Experiments and other Scientific Purposes” (Strasbourg, March 18, 1986). The animals received thiopental anesthesia, after which decapitation and dissection of the animals were performed. Biologically active components of the fungi P. ostreatus and S. cerevisiae are approved for use and before use, all patients were informed about clinical studies and gave their consent to participate in the study; these studies were carried out in the clinic in compliance with accepted standards (“WMA declaration of Helsinki”, 2013).

Experiments on the effect of biologically active compounds from P. ostreatus and S. cerevisiae on resistance to the toxic effect of copper sulfate were carried out on young, sexually mature male Wistar rats (3.0–3.5 months), weighing 150–200 g. In a group of 75 rats (n = 15), 5 experimental subgroups were formed: I – control received daily per os saline, in a volume of 0.05 mL/100 g of body weight, for 6 days; II – received biologically active compounds from P. ostreatus and S. cerevisiae daily at a dose of 0.01 mL/100 g of body weight, which was injected with per os, for 6 days; III – received biologically active compounds from P. ostreatus and S. cerevisiae daily at a dose of 0.05 mL/100 g of body weight which was injected with per os, for 6 days; IV – received biologically active compounds from P. ostreatus and S. cerevisiae daily at a dose of 0.4 mL/100 g of body weight which was injected with per os, for 6 days; V – received biologically active compounds from P. ostreatus and S. cerevisiae daily at a dose of 2.5 mg/100 g of body weight. All manipulations with animals (the administration of biologically active compounds from P. ostreatus and S. cerevisiae, determination of body weight and body temperature), were carried out from 9:00 a.m. to 11:00 a.m. before feeding the animals. All animals were kept in standard vivarium conditions at a temperature of 18–20 ºC, a natural change in the lighting regime, and had free access to food and water.

When determining the effect of biologically active compounds from P. ostreatus and S. cerevisiae on the indicators of the redox system, a group of 3-month-old rats of 15 animals was formed, which were divided into 3 subgroups of 5 animals each: I – group was not exposed to any influence; II – liver fibrosis was induced by three times administration of copper sulfate with an interval between administration of 48 hours at a dose of 1 mg/100 g of body weight, as described previously (Bozhkov et al., 2010), and 24 hours after administration at the last administration, the animals were decapitated after ether anesthesia; III – liver fibrosis was induced according to the same scheme, followed by per os administration of biologically active compounds from P. ostreatus and S. cerevisiae to these animals at a dose of 0.05 mL/100 g for three days, and 24 hours after the last administration of biologically active compounds from P. ostreatus and S. cerevisiae, the animals were decapitated after ether anesthesia.

When the animals were decapitated, blood was collected, blood serum was obtained. Mitochondria were isolated from the liver (Karanth & Narayan, 1972), and the content of lipid hydroperoxides, mitochondrial aconitase activity and glutathione peroxidase was determined.

The mitochondria swelling was recorded by changing the optical density in a thermostatted (37 ºC) cuvette with constant agitation by spectrophotometer Spectrophotometer UV VIS (Germany) at 610 nm. The incubation medium composition was the following: 10 mL Tris-HCl, pH 7.4, 0.25 M sucrose, 5 mM KH₂PO₄, 5 mM rotenone, 2 mM succinate and 25 mM CaSO₄. The lipid hydroperoxide (HPL) content of mitochondria was determined by method (Asakawa & Matsushita, 1980). The HPL content in serum was determined as previously described. The absorption spectrum of the coloured product was recorded on double-beam spectrophotometer Spectrophotometer UV VIS, measuring the difference in extinction at 535 and 520 nm. The HPL content was expressed in equivalent amounts of using a molar extinction coefficient of 1.56 × 10³ M⁻¹ cm⁻¹. The activity was expressed in nmol MDA/mg protein.

The activity rate of aconitate hydratase (aconitase, EC 4.2.1.3) was measured according to the procedure described in (Varghese et al., 2003) and expressed in nmol of aconitate per 1 mg of proteins using the molar extinction coefficient 3.6 mL M⁻¹ cm⁻¹.

The activity rate of glutathione peroxidase (EC 1.11.1.9, GP) was measured in liver mitochondria by spectrophotometry according to the method described in (Paglia & Valentine, 1967): we added 50 mM KNa phosphate buffer (pH 7.4) containing 1 mM of DTA, 0.15 mM of NADPH, 1 unit of yeast glutathione reductase, 0.2% triton X-100, and 3 mM sodium azide for inhibiting catalase. The activity rate was expressed in nmol NADPH/min per 1 mg of proteins or 1 mL of serum with allowance for the molar extinction coefficient 6.22 × 10³ M⁻¹ cm⁻¹.

Assessment of the hepatoprotective effect of biologically active components of the fungi P. ostreatus and S. cerevisiae. To assess the hepatoprotective effect of components of the fungi, in the clinic where patients with liver fibrosis and hepatitis are treated, a group of 20 volunteers was formed who took biologically active compounds daily 30 minutes before meals at a dose of 0.01 mL per kilogram of body weight for 10 days. Before taking biologically active compounds from P. ostreatus and S. cerevisiae, all volunteers had their blood biochemical parameters determined: the activity of ALT, AST, and the content of bilirubin (by conventional methods using standard kits Stat Fax 1904). After 10 days, the biochemical activities of ALT, AST, and the bilirubin content were re-determined in all patients. The patients were represented by 9 men and 11 women, aged 40-60 years. The study involved patients with a wide range of liver pathologies (clinical picture of patients: acute toxic infections; use of high doses of antibiotics (pneumonia); chronic hepatitis (including autoimmune); fatty degeneration; toxic alcoholic hepatosis, but in all subjects, the activity of ALT and ATC in the blood serum was increased.

The data are presented in the figures as x ± SE (x ± standard error). The statistical analysis of survival experimental animals was carried out by the moment method (Kaplan-Meier with log-rank test with Yates’ correction); the estimate of the accuracy of the approximation was calculated using the Greenwood formula. Comparison of the experimental and control groups was carried out using a log-rank criterion. The results obtained
were presented for each individual, as well as their group mean values (in laboratory animals only the average for the group), which were subjected to statistical processing using analysis of variance, where the differences were considered significant at P < 0.05 (taking into account the Bonferroni amendment).

Results

It turned out that if the animals (15 sexually mature healthy males) were injected with copper sulfate solution at a dose of 2.5 mg/100 g of body weight, then after 2–3 hours from the moment of administration, up to 60.0% of the animals died (median equal to 3), and after 20 hours from the beginning of the experiment in the control group 30.0% of the animals remained alive. By the third day of the experiment, only 20.0% of the animals remained alive (Fig. 1a, curve I). Consequently, copper sulfate at a dose of 2.5 mg/100 g of body weight exhibits acute toxicity for Wistar rats.

In the event that the animals received daily per os biologically active compounds from *P. ostreatus* and *S. cerevisiae*, which is represented by a complex of low molecular weight proteins (Fig. 2), at a dose of 0.01 mL/100 g of body weight for 6 days, and 24 hours after the last administration, they were injected with copper sulfate at a dose of 2.5 mg/100 g, as well as the control group, the mortality curve did not differ significantly from the control option (Fig. 1).

![Fig. 1. Survival of experimental animals according to Kaplan-Meier (N = 75): a – control group, which did not receive biologically active compounds from *P. ostreatus* and *S. cerevisiae*, they were injected with copper sulfate at a dose of 2.5 mg/100 g of body weight (I); animals that were injected daily with compounds at a dose of 0.01 mL/100 g of body weight for 6 days, followed by the administration of copper sulfate at a dose of 2.5 mg/100 g (II); a group of animals that were injected daily with compounds at a dose of 0.05 mL/100 g of body weight for 6 days, followed by the administration of copper sulfate at a dose of 2.5 mg/100 g (III); b – a group of animals that were previously injected with compounds at a dose of 0.4 mL/100 g of body weight according to the same scheme, followed by the administration of copper sulfate (IV) and a group that was previously injected with compounds at a dose of 0.8 mL/100 g with the subsequent administration of copper sulfate (V); c – dose dependence of the survival of rats in arbitrary units, 72 hours after administration of copper sulfate to animals at a dose of 2.5 mg/100 g of body weight; * – significant values are marked (P < 0.05) compared to the intact level (log-rank test with Yates’ correction)](image1)

![Fig. 2. A typical spectrum of proteins that make up biologically active compounds from *P. ostreatus* and *S. cerevisiae* were obtained on a Microflex MALDI-TOF Biotyper mass spectrometer (Bruker); the ordinate is relative units, the abscissa is m/z of proteins](image2)
If the animals were preliminarily injected with biologically active compounds from *P. ostreatus* and *S. cerevisiae* for 6 days at a dose of 0.05 mL/100 g of body weight, then a reliable manifestation of resistance to the lethal effect of copper sulfate was observed. So, the death of the first animals after the administration of copper sulfate occurred much later (only after 10 hours), compared with the control group, and for 20 hours 90.0% of the animals remained alive, and after three days 80.0% of the animals were active and did not differ from normal animals in behaviour (Fig. 1a, curve III).

An increase in the biologically active compounds from *P. ostreatus* and *S. cerevisiae* dose to 0.4 mL/100 g of body weight did not significantly affect the resistance of experimental animals to the toxic effect of copper sulfate, as did the dose of 0.8 mL/100 g (Fig. 1b, curves IV and V).

It should be noted that the components of biologically active compounds, even at a dose of 0.8 mL/100 g of mass, did not show any negative toxic effects on the body. Consequently, preliminary administration of biologically active compounds from *P. ostreatus* and *S. cerevisiae* to experimental animals with liver fibrosis did not significantly change the number of erythrocytes in animals that received such administration compared with the intact control animals (Fig. 3a, curve IV).

It is known that a decrease in aconitase activity correlates with an increase in lipid hydroperoxides in mitochondria; therefore, it was of interest to determine the activity of the key enzyme of antioxidant defense, glutathione peroxidase, in liver mitochondria. And it was found that indeed the number of erythrocytes in animals that received such administration compared with the intact control animals increased their resistance to the toxic effect of copper sulfate, and this effect depended on the dose and had a U-shaped character. The greatest protection effect was observed for a dose of 0.05 mL/100 g of body weight (Fig. 1c).

In the next series of experiments, the aconitase activity, one of the enzymes of the Krebs cycle in animals with Cu-induced liver fibrosis, was determined. It was found that after 3 consecutive injections of copper sulfate in experimental animals, at doses of 1 mg/100 g of body weight, which was about 30.0% of the lethal dose, and induced the development of liver fibrosis (Bozhkov et al., 2010), the aconitase activity in mitochondria was reduced by 48.0% compared with a control level (Fig. 3a). If animals with liver fibrosis previously received biologically active compounds from *P. ostreatus* and *S. cerevisiae* at a dose of 0.05 mL/100 g for three days, the aconitase activity was lower than the control level by only 23.0% and significantly higher than after administration of copper sulfate (Fig. 3a).

**Fig. 3.** The activity of aconitase and glutathione peroxidase, as well as the content of lipid hydroperoxides in experimental groups of animals 

(\(x \pm SE, N = 15\)): *a* – the aconitase activity in liver mitochondria in intact animals (I); in animals with Cu-induced liver fibrosis (II) and in animals with Cu-induced liver fibrosis, which were injected with biologically active compounds from *P. ostreatus* and *S. cerevisiae* per os at a dose of 0.05 mL/100 g of body weight for 3 days (III); *b* – activity of glutathione peroxidase in liver mitochondria in the same experimental groups; *c* – the content of lipid hydroperoxides in liver mitochondria in the same groups of animals; *d* – the content of lipid hydroperoxides in blood serum in the same groups of animals; the mean values, standard error are presented, * – significant values (\(P < 0.05\), taking into account the Bonferroni amendment) compared with the intact level and ** – compared with Cu-induced liver fibrosis after biologically active compounds from *P. ostreatus* and *S. cerevisiae* administration are noted.

It is known that a decrease in aconitase activity correlates with an increase in lipid hydroperoxides in mitochondria; therefore, it was of interest to determine the activity of the key enzyme of antioxidant defense, glutathione peroxidase, in liver mitochondria. And it was found that the activity of glutathione peroxidase in the mitochondria of the liver of rats which were injected three times with copper sulfate, was reduced by 20.0% compared with the control values. At the same time, administration of biologically active compounds from *P. ostreatus* and *S. cerevisiae* to experimental animals with liver fibrosis did not significantly change the activity of this enzyme (Fig. 3b).

Determination of the content of lipid hydroperoxides in mitochondria in animals with liver fibrosis showed that their content was increased by 29.0% compared to the control level (Fig. 3c). Administration of biologically active compounds from *P. ostreatus* and *S. cerevisiae* to animals with liver fibrosis reduced the content of lipid hydroperoxides in mitochondria by 29.0% and their content did not differ from the values of control animals (Fig. 3c).

Even more, pronounced changes in the content of lipid hydroperoxides were observed in blood serum. So, after the administration of copper sulfate, their content in it increased by 102.0% compared to the control, and after the administration of biologically active compounds from *P. ostreatus* and *S. cerevisiae*, their content decreased by 20.0% and exceeded the control by 60.0% (Fig. 3d). The results obtained allow us to conclude that biologically active compounds from *P. ostreatus* and *S. cerevisiae* have a "protective" effect against the toxic effect of copper sulfate, which can be realized at the level of regulation of the body's redox system parameters. This is supported by the previously obtained data on the presence of antioxidant and antitoxidation activity of biologically active compounds from *P. ostreatus* and *S. cerevisiae* in the *in vitro*.

However, the protective effect of the low molecular weight substance biologically active compounds from *P. ostreatus* and *S. cerevisiae* cannot be provided only at the level of the redox system. It was found that indeed the number of erythrocytes in animals that received copper sulfate was reduced in comparison with the control (Fig. 4).

The administration of biologically active compounds to animals with liver fibrosis ensured the preservation of their quantity, at the level of the redox system parameters. This is supported by the previously obtained data on the presence of antioxidant and antitoxidation activity of biologically active compounds from *P. ostreatus* and *S. cerevisiae* in the *in vitro*.

Consequently, biologically active compounds from *P. ostreatus* and *S. cerevisiae* can also exhibit membranotropic action. In this regard, it can be expected that such a membranotropic effect will be manifested in hepatocytes. Considering that biologically active compounds from *P. ostreatus* and *S. cerevisiae* are obtained from substrates used in food, without the use of toxic chemicals, it does not have any negative effects, eliminates some changes in liver fibrosis, and has a protective effect at a dose of 0.05 mL/100 g of body weight. It was of interest to study its effect on patients with hepatitis and liver fibrosis in the clinic.

In a clinical hospital, a group of 20 patients, men (9) and women (11), aged 40–60 years, was formed, suffering from liver pathologies, which are accompanied by an increase in the activity of ALT, AST, and the content of bilirubin (Fig. 5–7).
ically active compounds from \( P. \ ostreatus \) in the upper limit of the norm (Fig. 7a). A ten-day course of taking biologically active compounds from \( P. \ ostreatus \) and \( S. \ cerevisiae \) at a dose of 0.05 mL/100 g of body weight, followed by the administration of copper sulfate at a dose of 1 mg/100 g of body weight, led to a decrease in the bilirubin content after 10 days of taking biologically active compounds at a dose of 0.1 mL/kg body weight led to a decrease in ALT activity in 19 out of 20. In one of them by 16.0% compared with the initial level, in the remaining 18 by 21.0–60.0%, while in 14 patients (70.0%) this decrease was significant, by 40.0–55.0% (Fig. 5a). It should be noted that in 11 patients (55.0%), ALT activity reached the reference values (Fig. 5a). On average, in 19 patients, ALT activity decreased by 41.6% (Fig. 5b). And only in one of the patients (No. 3), while receiving biologically active compounds from \( P. \ ostreatus \) and \( S. \ cerevisiae \), was an increase in ALT activity observed, by 17.8% from the initial value (marked with an arrow).

Therefore, disruption of the functional activity of liver cells, regardless of etiology, which are manifested by disruption of hepatocyte membranes and, as a consequence, the “release” of ALT into the bloodstream, can be partially prevented by 10-day intake of biologically active compounds from \( P. \ ostreatus \) and \( S. \ cerevisiae \) at a dose of 0.1 mL/kg (5 mL day), except for patient No. 3.

Another indicator of the functional state of the liver is the activity of aspartate aminotransferase (AST). It was found that in three patients it corresponded to the upper reference values (0.47 mmol/h * mL), in 4 patients the activity of this enzyme was increased by 43.0% and in 13 patients an increase of 2.1 times compared with the upper limits of the reference values (Fig. 6a). In patient No. 3, AST activity was increased by 133.0% (Fig. 6a). A ten-day course of taking biologically active compounds from \( P. \ ostreatus \) and \( S. \ cerevisiae \) at a dose of 0.1 mL/kg of body weight led to a decrease in AST activity in the blood serum, while in the majority (13 people) it decreased by 40.0–60.0% from the initial values (Fig. 6b). In 12 patients, AST activity, after a ten-day course of biologically active compounds administration, corresponded to the reference values (Fig. 6a). On average, in 19 patients, AST activity decreased by 45.6% (Fig. 6b). In patient No. 3, while receiving biologically active compounds, an increase in AST activity by 33.0% from the initial value was observed (Fig. 6a).

These results confirm the conclusion that the structure of hepatocytes is restored after 10 days’ intake of biologically active compounds from \( P. \ ostreatus \) and \( S. \ cerevisiae \) administration in most patients. At the same time, the restoration of hepatocyte membranes may not reflect the detoxification function of native hepatocytes. The detoxification function of the liver, which, as a rule, is inhibited in hepatitis and fibrosis, can be judged by the content of bilirubin (a product of the hemoglobin destruction) in the blood serum. It was revealed that in the studied patients, the content of total bilirubin in the blood serum was higher than the upper normal values in 8 patients (and amounted to 48.2 μmol/L, i.e. 2.3 times higher than the reference values), in the remaining 12 patients it was 15.0 μmol/L, i.e. fit in the upper limit of the norm (Fig. 7a). A ten-day course of taking biologically active compounds from \( P. \ ostreatus \) and \( S. \ cerevisiae \) at a dose of 0.1 mL/kg of body weight led to a slight decrease in the bilirubin content by 3.0–6.0% from the initial one in three patients. In the rest of the patients, its content decreased by 23.0–53.0% from the initial level, and as a result, in 16 patients it corresponded to the reference values (Fig. 7a). On average, in the study group, except for patient No. 3, the serum bilirubin content decreased by 20.3% (Fig. 7b). In patient No. 3, while receiving biologically active compounds, an increase in the bilirubin content (as well as in the case of ALT and AST) by 29.0% was observed (Fig. 7a). Consequently, biologically active compounds from \( P. \ ostreatus \) and \( S. \ cerevisiae \) normalizes, in most patients, the activity of ALT, AST, and the serum bilirubin content after 10 days of taking biologically active compounds at a dose of 0.1 mL/kg, and the normalization effect has individual characteristics.
Fig. 6. AST activity (x ± SE, N = 20): a – AST activity in blood serum in 20 patients before taking biologically active compounds from P. ostreatus and S. cerevisiae (▲); AST activity after 10 days of taking compounds at a dose of 0.1 mL/kg of body weight (○); b – reference value (I), mean value for the AST activity group before taking compounds (II) and 10 days after taking compounds (III); * – significant differences were noted at p < 0.05 (taking into account the Bonferroni amendment) in comparison with the value before taking compounds; patient No. 3 is highlighted with an arrow.

Fig. 7. The content of bilirubin (x ± SE, N = 20): a – the content of bilirubin in blood serum in 20 patients before taking biologically active compounds from P. ostreatus and S. cerevisiae (▲) and after 10 days of taking compounds at a dose of 0.1 mL/kg of body weight (○); b – reference value (I), the average bilirubin value in the group before taking compounds (II) and after taking compounds (III); * – significant differences were noted at P < 0.05 (taking into account the Bonferroni amendment) in comparison with the value before taking compounds; patient No. 3 is highlighted with an arrow.

Discussion

The present study, carried out on experimental animals, showed that biologically active compounds from P. ostreatus and S. cerevisiae components can prevent the death of most animals in the study group from acute poisoning with copper sulfate, and this is realized through the regulation of the redox system and membrane-stabilizing action, i.e. biologically active compounds are a biological antidote, and in clinical studies on volunteers, membranotropic and, as a consequence, hepatoprotective effects have been confirmed.

The results obtained allow us to assert that biologically active compounds from P. ostreatus and S. cerevisiae have a broad (multifunctional) nature of their action on biological systems, and on the other hand, the manifestation of their actions depends on the individual characteristics of the organism.

Thus, in one of 20 patients, biologically active compounds from P. ostreatus and S. cerevisiae did not stop the pathogenesis process, and 20 percent of the animals with Cu-induced intoxication died, as in the control variant, i.e. biologically active compounds did not exert a protective effect on them. This indicates that the action of biologically active compounds depends on the functional states of the organism, which are not defined in this case, and have an individual character.

These results raise several important questions, the search for answers to which may be important for understanding the mechanisms of action of other biologically active compounds: 1 – why biologically active compounds from P. ostreatus and S. cerevisiae did not have, or had an insignificant effect on a healthy organism and were active in the presence of pathologies; 2 – why, in some cases, biologically active compounds from P. ostreatus and S. cerevisiae did not affect the pathologically altered state, i.e. did not show an “induced” protective response; 3 – what explains the U-shaped dose dependence of the biologically active compounds on the action of P. ostreatus and S. cerevisiae; 4 – how to explain the multifunctional effect of biologically active compounds from P. ostreatus and S. cerevisiae on the body.

It can be assumed that if the organism is “healthy”, which means that its metabolic system is in a relatively stable homeostatic state, it is capable of self-maintenance and therefore external factors, if they do not exert a “strong” disturbance, will not affect the metabolic activity. Since the bio-
logically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) components are of biological origin, i.e. are not xenobiotics and are not capable of exerting a “strong” effect on the metabolically stable system, but are capable of exerting regulatory “softer” effects, then such a system is not sensitive to their action.

Since biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) enter the body per os, its components can perform trophic functions.

The possible trophic role of biologically active compounds is supported by data on a slight increase in body weight and performance in control animals (Kurgazova et al., 2015; Bozhkov et al., 2016).

It can be assumed that the metabolic system of a “healthy” organism can maintain itself in an “equilibrium” state and the biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) components are not able to shift its equilibrium. In this case, biologically active compounds will exhibit only trophic functions.

If a pathological process takes place in the body, i.e. the homeostatic state is disturbed and the metabolic system of the organism passes into a “new functional state”, which can be characterized as far from equilibrium (Ebrahimi et al., 2016), then the biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) components, along with trophic ones, also exhibit various regulatory effects.

At the initial stages of the development of pathology, the metabolic system is “able” to restore its homeostatic state; this state can be defined as reversible. At the later stages of the development of the pathological process, the system passes into irreversible states, i.e. the system becomes homeostatically stable again. This condition is, in practice, defined as “irreversible” or chronic. In the case of chronic condition, i.e. a new steady-state, biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) will also not have a significant regulatory effect, which may have taken place in patient No. 3 and some of the animals that died after the administration of copper sulfate large doses.

Consequently, in the case of a stable metabolic state (a healthy organism or a chronic pathological state), biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) will not have any effect, while in the case of a metabolic disequilibrium state, the biologically active compounds will contribute to the restoration of homeostatic equilibrium.

Lackey wrote about this figuratively in his time: “A pathological organism responds to the impact with ease if it is in suboptimal conditions, that is, the metabolic system is quasi-stable and far from the state of homeostatic equilibrium, it reacts faster than a system in relative equilibrium”. Such states are very well described for physical systems (Thibault et al., 2012).

Based on this position, it can be assumed that the actions of the biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) components depend on the state of the metabolic system at the time of exposure. If the system is in homeostatic equilibrium or close to it, a healthy organism or an organism with chronic pathology (which has become a new stable state), then such a system retains its previous state, and biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) will not influence it.

Of course, these general explanations require deep detailing, but this allows us to understand the direction of further research for the mechanism of biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) action. If these judgments are correct, then biologically active compounds can be used to determine the state of the metabolic system in relation to homeostatic equilibrium, which can be important in comparative studies.

Establishing the dose dependence of the body’s response to an external factor is important in understanding the mechanisms of action of biologically active compounds. As has been shown in experimental animals, the so-called U-shaped dose dependence is characteristic of the biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \), i.e. there is a maximum response, at conditionally average concentrations of substances, while small and large doses do not induce a recorded response.

As is known, this dependence reflects the phenomenon of hormesis – nonspecific stimulation of biological processes by small doses of factors harmful to the body, in which the toxic effect does not manifest itself (Kendig et al., 2010). Hormesis is shown at low doses of radiation (radiation hormesis) (Hickey et al., 1983), toxic compounds, in particular copper sulfate (Kovaleva et al., 2012; Bozhkov et al., 2014), and is a general biological phenomenon (Calabrese & Baldwin, 1998).

However, unlike toxic compounds, biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) do not show negative, depressing effects, even at high doses (0.8 ml/100 g of body weight). In this respect, this substance cannot be claimed to exert hormesis, and the analogy with the hormesis effect can be defined as a quasi-hormesis effect.

The quasi-hormesis effect of biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) can be explained by the principle of functional request. Since the biologically active compounds consists of a large number of various biologically active components (Fig. 2), which of these substances will exhibit one or another activity depends on which of the endogenous ligands of the metabolic system is capable of interacting with biologically active compounds at a given time.

An example is the functioning of the body’s redox system. It has been shown that the same biological components, depending on the state, can perform the functions of both prooxidants and antioxidants. It was previously shown that the components of cow colostrum, depending on the dose, can perform the functions of both an antioxidant and a prooxidant (Bozhkov et al., 2017).

As it known, most of the known enzymes are polyfunctional, and which of its activities the enzyme will exhibit depends on the functional request of the system, which is aimed at maintaining homeostatic equilibrium at a given time.

It should be noted that the polyfunctional nature that was fixed at the physiological level is formed in different ways at the levels of the hierarchical organization of biological systems. The action of biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) can be “direct” – this is when the components of a multicomponent substance directly interact with certain ligands, i.e. they perform a regulatory role based on the principle of functional request. Along with this, biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) can also have an indirect effect on the functional characteristics of biosystems. Thus, in the case of a healthy organism, biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) can perform a trophic function and have an indirect effect on many-body systems. So, the administration of biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) to animals against the background of bacterial infection (\( P. \) \( \text{aeruginosa} \) and \( E. \) \( \text{coli} \)) has an immunotropic effect on the body (Bozhkov et al., 2017; Klimova et al., 2018).

It can be assumed that changes in the characteristics of such regulatory systems of the body as the redox system, the immune system, the digestive system, and biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) can cause a synergistic effect.

As is known, synergy is joint action in one direction of some substances that make up the substrate, which provides not just summation, but emergence (i.e., it registers an effect that is more than just the sum of effects) (Kesic, 2016). It can be assumed that biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) exhibit “emergent synergism” if the metabolic elements are in a state far from homeostatic equilibrium.

If we accept these assumptions and analyze the data obtained, we can put forward a working hypothesis about the “emergent-synergistic” effect of biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) on metabolic systems that are far from homeostatic equilibrium, in particular, caused by intoxication of the body, which is accompanied by the formation of liver pathology.

Biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) components, entering the digestive tract, affect the intestinal microflora, and, depending on the dose, they shift the equilibrium between the types of microflora, acting as a stimulant for some species and as a growth inhibitor for other species, that is, they perform a selective function (Fig. 8).

Taking into account the diverse composition of biologically active compounds from \( P. \) \( \text{ostreatus} \) and \( S. \) \( \text{cerevisiae} \) on metabolic systems that are far from homeostatic equilibrium, in particular, caused by intoxication of the body, which is accompanied by the formation of liver pathology.

manifestation of emergence at the physiological level

biologically active compounds from Pleuronotus Ostreatus and Sarcharamirus cerveisiae

Fig. 8. Diagram showing the direct (→) and indirect (→) effects of various components of low molecular weight complexes on various functional systems (gastrointestinal tract; redox system; cell membrane system; immune system) of the body

Conclusions

The present study, carried out on experimental animals, showed that biologically active compounds from P. ostreatus and S. cerevisiae components can prevent the death of most animals in the study group from acute poisoning with copper sulfate, and this is realized through the regulation of the redox system and membrane-stabilizing action, i.e. biologically active compounds from P. ostreatus and S. cerevisiae are a biological antitoxin, and in clinical studies on volunteers, membranotropic and, as a consequence, hepatoprotective effects have been confirmed. The results obtained allow us to assert that biologically active compounds from P. ostreatus and S. cerevisiae have a broad (multifunctional) nature of action on biological systems, and on the other hand, the manifestation of their actions depends on the individual characteristics of the organism.

The authors state that there are no conflicts of interest. There are no persons who have a financial interest in the received data.

References


